BioCryst Pharmaceuticals Shares Outstanding 2006-2019 | BCRX

BioCryst Pharmaceuticals shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
BioCryst Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2019 116
2018 103
2017 84
2016 74
2015 73
2014 67
2013 55
2012 49
2011 45
2010 45
2009 39
2008 38
2007 33
2006 29
2005 26
BioCryst Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2019-12-31 116
2019-09-30 110
2019-06-30 110
2019-03-31 110
2018-12-31 103
2018-09-30 105
2018-06-30 99
2018-03-31 99
2017-12-31 84
2017-09-30 84
2017-06-30 80
2017-03-31 75
2016-12-31 74
2016-09-30 74
2016-06-30 74
2016-03-31 74
2015-12-31 73
2015-09-30 73
2015-06-30 77
2015-03-31 72
2014-12-31 67
2014-09-30 72
2014-06-30 64
2014-03-31 60
2013-12-31 55
2013-09-30 57
2013-06-30 53
2013-03-31 51
2012-12-31 49
2012-09-30 51
2012-06-30 49
2012-03-31 47
2011-12-31 45
2011-09-30 45
2011-06-30 45
2011-03-31 45
2010-12-31 45
2010-09-30 45
2010-06-30 45
2010-03-31 44
2009-12-31 39
2009-09-30 38
2009-06-30 38
2009-03-31 38
2008-12-31 38
2008-09-30 38
2008-06-30 38
2008-03-31 38
2007-12-31 33
2007-09-30 34
2007-06-30 29
2007-03-31 29
2006-12-31 29
2006-09-30 29
2006-06-30 29
2006-03-31 29
2005-12-31 26
2005-09-30 26
2005-06-30 26
2005-03-31 24
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.307B $0.049B
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $55.107B 31.88
Takeda Pharmaceutical (TAK) Japan $46.440B 8.14
Astellas Pharma (ALPMY) Japan $28.068B 14.02
Eisai (ESALY) Japan $19.576B 36.47
UCB SA (UCBJF) Belgium $16.930B 0.00
Grifols, S.A (GRFS) Spain $13.607B 16.92
Merck (MKGAF) Germany $12.536B 16.44
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $7.966B 221.31
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.874B 0.00
Catalent (CTLT) United States $7.312B 30.08
Ionis Pharmaceuticals (IONS) United States $6.823B 20.68
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.361B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $5.587B 6.81
Orion OYJ (ORINY) Finland $5.269B 23.61
STADA ARZNEIMI (STDAF) Germany $4.685B 0.00
Forty Seven (FTSV) United States $4.596B 0.00
IPSEN SA ADR (IPSEY) France $4.543B 0.00
United Therapeutics (UTHR) United States $4.105B 0.00
Hypermarcas (HYPMY) Brazil $3.434B 10.44
Evotec AG (EVTCY) Germany $3.422B 55.18
Nektar Therapeutics (NKTR) United States $3.033B 0.00
FibroGen (FGEN) United States $2.996B 0.00
PTC Therapeutics (PTCT) United States $2.816B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.736B 50.77
ChemoCentryx (CCXI) United States $2.450B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.387B 9.66
Xencor (XNCR) United States $1.697B 69.30
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.613B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.598B 19.42
Theravance Biopharma (TBPH) Cayman Islands $1.397B 0.00
Sage Therapeutics (SAGE) United States $1.389B 0.00
Corcept Therapeutics (CORT) United States $1.375B 15.39
Pacira Pharmaceuticals (PCRX) United States $1.369B 37.45
USANA Health Sciences (USNA) United States $1.352B 14.19
Karyopharm Therapeutics (KPTI) United States $1.186B 0.00
Heron Therapeutics (HRTX) United States $1.056B 0.00
Zogenix (ZGNX) United States $1.052B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.996B 30.85
Akebia Therapeutics (AKBA) United States $0.918B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.913B 12.71
Esperion Therapeutics (ESPR) United States $0.907B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.781B 0.00
Endo (ENDP) Ireland $0.701B 1.29
Tilray (TLRY) Canada $0.635B 0.00
Aerie Pharmaceuticals (AERI) United States $0.607B 0.00
ImmunoGen (IMGN) United States $0.605B 0.00
Molecular Templates (MTEM) United States $0.584B 0.00
Radius Health (RDUS) United States $0.579B 0.00
Portola Pharmaceuticals (PTLA) United States $0.557B 0.00
Translate Bio (TBIO) United States $0.546B 0.00
Collegium Pharmaceutical (COLL) United States $0.536B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.410B 16.85
Indivior (INVVY) United States $0.389B 2.31
Siga Technologies (SIGA) United States $0.388B 0.00
Innate Pharma SA (IPHYF) France $0.385B 0.00
Ardelyx (ARDX) United States $0.379B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.374B 12.48
Corbus Pharmaceuticals Holdings (CRBP) United States $0.354B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.344B 0.00
Organogenesis Holdings (ORGO) United States $0.313B 0.00
Trillium Therapeutics (TRIL) Canada $0.308B 0.00
Calithera Biosciences (CALA) United States $0.284B 0.00
Harpoon Therapeutics (HARP) United States $0.283B 0.00
DURECT (DRRX) United States $0.280B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.272B 0.00
TherapeuticsMD (TXMD) United States $0.271B 0.00
Lannett Co Inc (LCI) United States $0.267B 4.31
Flexion Therapeutics (FLXN) United States $0.264B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.263B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.255B 0.00
Ocular Therapeutix (OCUL) United States $0.250B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.241B 0.00
Concert Pharmaceuticals (CNCE) United States $0.231B 0.00
OptiNose (OPTN) United States $0.192B 0.00
CASI Pharmaceuticals (CASI) United States $0.190B 0.00
Rafael Holdings (RFL) United States $0.189B 0.00
Recro Pharma (REPH) United States $0.168B 0.00
PROFOUND MEDICL (PROF) Canada $0.155B 0.00
MEI Pharma (MEIP) United States $0.154B 0.00
Jounce Therapeutics (JNCE) United States $0.152B 2.74
Nature's Sunshine Products (NATR) United States $0.148B 18.58
La Jolla Pharmaceutical (LJPC) United States $0.138B 0.00
Taiwan Liposome (TLC) Taiwan $0.133B 0.00
KalVista Pharmaceuticals (KALV) United States $0.133B 0.00
VAXART, INC (VXRT) United States $0.119B 0.00
Redhill Biopharma (RDHL) Israel $0.114B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.109B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.092B 0.00
CannTrust Holdings (CTST) Canada $0.090B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.087B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.087B 0.00
Champions Oncology (CSBR) United States $0.080B 0.00
IMV INC (IMV) Canada $0.080B 0.00
Hemispherx BioPharma (AIM) United States $0.076B 0.00
SCYNEXIS (SCYX) United States $0.075B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.071B 0.00
CTI BioPharma (CTIC) United States $0.071B 0.00
Biomerica (BMRA) United States $0.070B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.068B 0.00
Aquestive Therapeutics (AQST) United States $0.063B 0.00
Otonomy (OTIC) United States $0.062B 0.00
Xeris Pharmaceuticals (XERS) United States $0.059B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.055B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.055B 17.19
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.053B 0.00
Nivalis Therapeutics (ALPN) United States $0.052B 0.00
CV Sciences (CVSI) United States $0.051B 0.00
Onconova Therapeutics (ONTX) United States $0.047B 0.00
PharmAthene (ALT) United States $0.046B 0.00
Aclaris Therapeutics (ACRS) United States $0.046B 0.00
Infinity Pharmaceuticals (INFI) United States $0.044B 0.00
Natural Alternatives (NAII) United States $0.044B 19.84
Sundial Growers (SNDL) Canada $0.041B 0.00
MediWound (MDWD) Israel $0.041B 0.00
GTx (ONCT) United States $0.040B 0.00
PolarityTE (PTE) United States $0.038B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.038B 128.71
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
IsoRay (ISR) United States $0.036B 0.00
Forward Pharma (FWP) Denmark $0.035B 0.00
Neos Therapeutics (NEOS) United States $0.035B 0.00
AgeX Therapeutics (AGE) United States $0.033B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.033B 0.00
Heat Biologics (HTBX) United States $0.031B 0.00
Mannatechorporated (MTEX) United States $0.025B 7.79
Jaguar Animal Health (JAGX) United States $0.024B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.023B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.023B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.022B 0.00
ElectroCore (ECOR) United States $0.022B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.022B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.022B 0.00
Cardiome Pharma (CORV) Canada $0.021B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Lipocine (LPCN) United States $0.020B 0.00
Novan (NOVN) United States $0.020B 0.00
India Globalization Capital (IGC) United States $0.018B 0.00
Bio-Path Holdings (BPTH) United States $0.017B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.013B 0.00
Shineco (TYHT) China $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
Can-Fite Biopharma (CANF) Israel $0.011B 0.00
Vical (BBI) United States $0.010B 0.00
KemPharm (KMPH) United States $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.009B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.008B 0.00
Midatech Pharma (MTP) United Kingdom $0.006B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.006B 0.00
HANCOCK JAFFE (HJLI) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.003B 0.00
Xenetic Biosciences (XBIO) United States $0.003B 0.00
RXi Pharmaceuticals (PHIO) United States $0.001B 0.00